The Role of Newer Abortive Agents
In December 2019, the US Food and Drug Administration (FDA) approved the first small molecule calcitonin gene-related peptide (CGRP) antagonist for the treatment of acute migraine, ubrogepant (Ubrelvy®),1 followed closely by rimegepant (Nurtec ODT®).2 A novel serotonin (5-HT)1F receptor agonist, lasmiditan (Reyvow®), was approved in October 2019 as a new oral agent for the acute…
